Log In
BCIQ
Print this Print this
 

SVN-001

  Manage Alerts
Collapse Summary General Information
Company Sevion Therapeutics Inc.
DescriptionIon channel blocking antibody targeting Kv1.3
Molecular Target Potassium channel Kv1.3 (KCNA3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune disorders
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today